MXPA04005263A - 2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa. - Google Patents
2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa.Info
- Publication number
- MXPA04005263A MXPA04005263A MXPA04005263A MXPA04005263A MXPA04005263A MX PA04005263 A MXPA04005263 A MX PA04005263A MX PA04005263 A MXPA04005263 A MX PA04005263A MX PA04005263 A MXPA04005263 A MX PA04005263A MX PA04005263 A MXPA04005263 A MX PA04005263A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pharmaceutically acceptable
- angina pectoris
- cycloalkanecarboxamides
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a compuestos de formula(ver formula I)en donde R1, R2, R3, R4, R5, R6 y n son como se ha definido en la descripcion y las reivindicaciones y sales farmaceuticamente aceptables y/o esteres farmaceuticamente aceptables de los mismos. Los compuestos son utiles para el tratamiento de enfermedades que estan asociadas con cistein proteasas tales como osteoporosis, osteoartritis, artritis reumatoide, metastasis tumoral, glomerulonefritis, aterosclerosis, infarto de miocardio, angina de pecho, angina de pecho inestable, ataques al corazon, rotura de placa, ataques isquemicos transitorios, amaurosis fugax, enfermedad arterial oclusiva periferica, restenosis tras angioplastia y endoprotesis, formacion de aneurisma aortico abdominal, inflamacion, enfermedad autoinmune, malaria, citopatia tisular del fundus ocular y enfermedad respiratoria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33675001P | 2001-12-04 | 2001-12-04 | |
PCT/EP2002/013221 WO2003048123A1 (en) | 2001-12-04 | 2002-11-25 | Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04005263A true MXPA04005263A (es) | 2004-10-11 |
Family
ID=23317485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04005263A MXPA04005263A (es) | 2001-12-04 | 2002-11-25 | 2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa. |
Country Status (25)
Country | Link |
---|---|
US (1) | US6747053B2 (es) |
EP (1) | EP1453801B1 (es) |
JP (1) | JP2005517640A (es) |
KR (1) | KR20050044660A (es) |
CN (1) | CN1315806C (es) |
AR (1) | AR037683A1 (es) |
AT (1) | ATE357432T1 (es) |
AU (1) | AU2002352126A1 (es) |
BR (1) | BR0214642A (es) |
CA (1) | CA2467435A1 (es) |
DE (1) | DE60219068T2 (es) |
ES (1) | ES2282497T3 (es) |
GT (1) | GT200200253A (es) |
HU (1) | HUP0402344A2 (es) |
IL (1) | IL161992A0 (es) |
MX (1) | MXPA04005263A (es) |
NO (1) | NO20042719L (es) |
PA (1) | PA8559701A1 (es) |
PE (1) | PE20030723A1 (es) |
PL (1) | PL370766A1 (es) |
RU (1) | RU2004120784A (es) |
TW (1) | TW200303861A (es) |
UY (1) | UY27561A1 (es) |
WO (1) | WO2003048123A1 (es) |
ZA (1) | ZA200404343B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042213A1 (en) * | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
US7005445B2 (en) * | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
DE60305446T4 (de) * | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
GB0403038D0 (en) * | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
US20090226552A1 (en) * | 2004-07-22 | 2009-09-10 | Colorado State University Research Foundation | Agents and methods for diagnosing osteoarthritis |
AU2006261954A1 (en) * | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
CA2617725C (en) * | 2005-08-05 | 2012-04-03 | Hybrigenics Sa | Novel cysteine protease inhibitors and their therapeutic applications |
WO2007041775A1 (en) * | 2005-10-10 | 2007-04-19 | The University Of Queensland | Cysteine protease inhibitors incorporating azide groups |
WO2007081530A2 (en) * | 2006-01-03 | 2007-07-19 | Med Institute, Inc. | Endoluminal medical device for local delivery of cathepsin inhibitors |
JP4012239B2 (ja) | 2006-01-11 | 2007-11-21 | 生化学工業株式会社 | オキサゾロン誘導体 |
US7838542B2 (en) * | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
WO2009001129A1 (en) * | 2007-06-26 | 2008-12-31 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
CN101591327B (zh) * | 2008-05-26 | 2012-07-25 | 华东理工大学 | 苯烷酰胺类化合物及其用途 |
ES2560381T3 (es) * | 2011-07-26 | 2016-02-18 | Sanofi | Derivados de ácido 3-heteroaroilamino-propiónico y su uso como productos farmacéuticos |
EP2892880B1 (en) | 2012-09-07 | 2017-11-22 | Novartis AG | Indole carboxamide derivatives and uses thereof |
NO2699580T3 (es) | 2014-01-24 | 2018-02-24 | ||
EP3106455A4 (en) * | 2014-02-14 | 2017-09-27 | TOA Eiyo Ltd. | Cyclic hydrocarbon compound |
WO2019025931A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE |
KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
MX2023002371A (es) | 2020-08-26 | 2023-05-19 | Haisco Pharmaceuticals Pte Ltd | Derivado de nitrilo que actua como inhibidor de la dipeptidil peptidasa 1 y uso del mismo. |
KR20230117738A (ko) | 2020-12-04 | 2023-08-09 | 레이스톤 바이오파마 컴퍼니 리미티드 | 카텝신 c의 소분자 억제제 및 이의 의약적 용도 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU177576B (en) | 1975-06-02 | 1981-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 2-amino-cyclohexane carboxylic acid,its amides and similar compounds |
DE4417163A1 (de) | 1994-05-17 | 1995-11-23 | Hoechst Schering Agrevo Gmbh | Heterocyclylamino- und Heterocyclyloxy-cycloalkyl-Derivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
IT1283467B1 (it) | 1996-07-19 | 1998-04-21 | Menarini Farma Ind | Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni |
CN1273444C (zh) | 1997-11-05 | 2006-09-06 | 诺瓦提斯公司 | 二肽腈 |
EP1244621B1 (en) * | 1999-12-24 | 2006-09-13 | F. Hoffmann-La Roche Ag | Nitrile derivatives as cathepsin k inhibitors |
US6525036B2 (en) | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
US6462076B2 (en) * | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
US7371747B2 (en) | 2001-11-13 | 2008-05-13 | Merck Frosst Canada & Co. | Cyanoalkylamino derivatives as protease inhibitors |
-
2002
- 2002-11-25 PL PL02370766A patent/PL370766A1/xx not_active Application Discontinuation
- 2002-11-25 EP EP02787799A patent/EP1453801B1/en not_active Expired - Lifetime
- 2002-11-25 RU RU2004120784/04A patent/RU2004120784A/ru not_active Application Discontinuation
- 2002-11-25 BR BR0214642-8A patent/BR0214642A/pt not_active IP Right Cessation
- 2002-11-25 MX MXPA04005263A patent/MXPA04005263A/es unknown
- 2002-11-25 AT AT02787799T patent/ATE357432T1/de not_active IP Right Cessation
- 2002-11-25 CN CNB02824060XA patent/CN1315806C/zh not_active Expired - Fee Related
- 2002-11-25 KR KR1020047008481A patent/KR20050044660A/ko not_active Application Discontinuation
- 2002-11-25 IL IL16199202A patent/IL161992A0/xx unknown
- 2002-11-25 JP JP2003549315A patent/JP2005517640A/ja active Pending
- 2002-11-25 AU AU2002352126A patent/AU2002352126A1/en not_active Abandoned
- 2002-11-25 CA CA002467435A patent/CA2467435A1/en not_active Abandoned
- 2002-11-25 ES ES02787799T patent/ES2282497T3/es not_active Expired - Lifetime
- 2002-11-25 WO PCT/EP2002/013221 patent/WO2003048123A1/en active IP Right Grant
- 2002-11-25 DE DE60219068T patent/DE60219068T2/de not_active Expired - Fee Related
- 2002-11-25 HU HU0402344A patent/HUP0402344A2/hu unknown
- 2002-11-29 PA PA20028559701A patent/PA8559701A1/es unknown
- 2002-11-29 PE PE2002001152A patent/PE20030723A1/es not_active Application Discontinuation
- 2002-11-29 TW TW091134784A patent/TW200303861A/zh unknown
- 2002-12-02 AR ARP020104642A patent/AR037683A1/es unknown
- 2002-12-03 GT GT200200253A patent/GT200200253A/es unknown
- 2002-12-03 US US10/308,963 patent/US6747053B2/en not_active Expired - Fee Related
- 2002-12-03 UY UY27561A patent/UY27561A1/es not_active Application Discontinuation
-
2004
- 2004-06-02 ZA ZA200404343A patent/ZA200404343B/en unknown
- 2004-06-28 NO NO20042719A patent/NO20042719L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PA8559701A1 (es) | 2003-07-28 |
KR20050044660A (ko) | 2005-05-12 |
TW200303861A (en) | 2003-09-16 |
NO20042719L (no) | 2004-06-28 |
DE60219068D1 (de) | 2007-05-03 |
PL370766A1 (en) | 2005-05-30 |
HUP0402344A2 (hu) | 2005-02-28 |
IL161992A0 (en) | 2005-11-20 |
AU2002352126A1 (en) | 2003-06-17 |
EP1453801A1 (en) | 2004-09-08 |
WO2003048123A1 (en) | 2003-06-12 |
RU2004120784A (ru) | 2005-08-10 |
UY27561A1 (es) | 2003-06-30 |
AR037683A1 (es) | 2004-12-01 |
JP2005517640A (ja) | 2005-06-16 |
GT200200253A (es) | 2003-07-03 |
US6747053B2 (en) | 2004-06-08 |
ZA200404343B (en) | 2006-07-26 |
CA2467435A1 (en) | 2003-06-12 |
BR0214642A (pt) | 2004-11-03 |
CN1315806C (zh) | 2007-05-16 |
DE60219068T2 (de) | 2007-12-13 |
PE20030723A1 (es) | 2003-08-29 |
ES2282497T3 (es) | 2007-10-16 |
US20030212097A1 (en) | 2003-11-13 |
CN1639119A (zh) | 2005-07-13 |
ATE357432T1 (de) | 2007-04-15 |
EP1453801B1 (en) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04005263A (es) | 2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa. | |
JO2234B1 (en) | Beta-amino derivatives of nitrile acid | |
UY26504A1 (es) | " nitrilo derivados como inhibidores de catepsina k " | |
AP1744A (en) | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | |
IS6069A (is) | N-cýanómetýlamíð sem próteasalatar | |
MXPA03001982A (es) | Amino-aza-cicloalcanos sustituidos utiles contra la malaria. | |
IL198643A (en) | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | |
DK1438310T3 (da) | Beta-carbolin-derivater som PTP-inhibitorer | |
DE60118003D1 (de) | Harnstoffderivate und ihre verwendung | |
CY1112800T1 (el) | Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας | |
MXPA04001930A (es) | Inhibidores de proteasa de cisteina con estructura de 2-ciano-4amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflaciones y otras enfermedades. | |
DE60235019D1 (de) | Benzothiazepin-derivate für die behandlung von hyperlipidemia | |
WO2004005279A3 (en) | Substituted anthranilic amide derivatives and methods of use | |
MY147780A (en) | Carboxamide compounds and their use as calpain inhibitors | |
MXPA03010724A (es) | Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina. | |
WO2000055124A3 (en) | Novel compounds and compositions as protease inhibitors | |
MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
MXPA03010766A (es) | Nuevos compuestos y composiciones como inhibicores de las catepsinas. | |
ATE312095T1 (de) | Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden | |
PT1651596E (pt) | Novos derivados de 4,4?-ditiobis-(3-aminobutano-1-sulfonatos) e composições que os contêm | |
MXPA04004450A (es) | Nuevos compuestos y composiciones como inhibidores de catepsina s. | |
ECSP003845A (es) | Derivados de nitrilo como inhibidores de catepsina k | |
BG105985A (en) | Prodrugs of thrombin inhibitors | |
MX2023003867A (es) | Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. | |
EP1452522A3 (en) | Novel compounds and compositions as protease inhibitors |